孟鲁司特钠联合左西替利嗪对慢性喘息型支气管炎患者症状消失时间及WBC、CRP水平的影响  

Impact of Montelukast Sodium Combined with Levetirizine on Symptom Resolution Time and Levels of WBC and CRP in Patients with Chronic Asthmatic Bronchitis

作　　者：赵昕 王映伙 冯松青 ZHAO Xin;WANG Yinghuo;FENG Songqing(Department of Internal Medicine,Duanzhou District People's Hospital,Zhaoqing 526040,China)

机构地区：[1]肇庆市端州区人民医院内科,广东肇庆526040

出　　处：《临床医学工程》2021年第6期787-788,共2页Clinical Medicine & Engineering

摘　　要：目的探讨孟鲁司特钠联合左西替利嗪治疗慢性喘息型支气管炎患者的效果。方法92例慢性喘息型支气管炎患者分为两组,对照组采用孟鲁司特钠治疗,观察组采用孟鲁司特钠联合左西替利嗪治疗,比较两组的临床效果。结果治疗4周后,观察组的喘鸣音消失时间、咳嗽消失时间、气促消失时间、住院时间均短于对照组,CRP、WBC水平均低于对照组,SpO2水平高于对照组(P<0.05)。结论孟鲁司特钠联合左西替利嗪治疗慢性喘息型支气管炎能缩短症状消失时间,降低WBC、CRP水平。Objective To explore the effect of montelukast sodium combined with levetirizine in the treatment of patients with chronic asthmatic bronchitis.Methods 92 patients with chronic asthmatic bronchitis were divided into two groups.The control group was treated with montelukast sodium,and the observation group was treated with montelukast sodium combined with levetirizine.The clinical effects of two groups were compared.Results After 4 weeks of treatment,the disappearance time of wheezing,cough and shortness of breath,and the hospitalization time of observation group were shorter than those of control group,the levels of CRP and WBC were lower than those of control group,and the SpO2 level was higher than that of control group(P<0.05).Conclusions Montelukast sodium combined with levetirizine in the treatment of chronic asthmatic bronchitis can shorten the symptom resolution time,and reduce the levels of WBC and CRP.

关 键 词：慢性喘息型支气管炎 孟鲁司特钠 左西替利嗪 白细胞计数 C反应蛋白 

分 类 号：R562.2[医药卫生—呼吸系统]